- Home
- RANI vs WHWK Comparison
RANI vs WHWK Comparison
Compare RANI & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RANI
- WHWK
- Stock Information
- Founded
- RANI 2012
- WHWK 2007
- Country
- RANI United States
- WHWK United States
- Employees
- RANI N/A
- WHWK N/A
- Industry
- RANI Medicinal Chemicals and Botanical Products
- WHWK Biotechnology: Pharmaceutical Preparations
- Sector
- RANI Health Care
- WHWK Health Care
- Exchange
- RANI Nasdaq
- WHWK Nasdaq
- Market Cap
- RANI 55.3M
- WHWK 48.3M
- IPO Year
- RANI 2021
- WHWK N/A
- Fundamental
- Price
- RANI $1.27
- WHWK $1.78
- Analyst Decision
- RANI Strong Buy
- WHWK
- Analyst Count
- RANI 6
- WHWK 0
- Target Price
- RANI $11.33
- WHWK N/A
- AVG Volume (30 Days)
- RANI 147.7K
- WHWK 216.9K
- Earning Date
- RANI 05-05-2025
- WHWK 03-18-2025
- Dividend Yield
- RANI N/A
- WHWK N/A
- EPS Growth
- RANI N/A
- WHWK N/A
- EPS
- RANI N/A
- WHWK N/A
- Revenue
- RANI N/A
- WHWK $25,983,000.00
- Revenue This Year
- RANI N/A
- WHWK N/A
- Revenue Next Year
- RANI N/A
- WHWK N/A
- P/E Ratio
- RANI N/A
- WHWK N/A
- Revenue Growth
- RANI N/A
- WHWK 6.69
- 52 Week Low
- RANI $1.24
- WHWK $1.21
- 52 Week High
- RANI $8.75
- WHWK $3.81
- Technical
- Relative Strength Index (RSI)
- RANI 37.10
- WHWK N/A
- Support Level
- RANI $1.30
- WHWK N/A
- Resistance Level
- RANI $1.56
- WHWK N/A
- Average True Range (ATR)
- RANI 0.09
- WHWK 0.00
- MACD
- RANI -0.02
- WHWK 0.00
- Stochastic Oscillator
- RANI 16.06
- WHWK 0.00
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.